# A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer

> **NCT02563054** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 316 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** 5-Fluorouracil
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02563054
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 316 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02563054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02563054, "A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02563054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*